Hologic Inc. has cleared the final regulatory hurdles for its monumental $18.3 billion acquisition by private equity giants Blackstone and TPG. The transaction, which will take the women's health technology company private, is scheduled for completion on or about April 7, 2026. This marks the culmination of a process that began with the deal announcement in October of the previous year.
Leadership Transition and Market Exit
With the closing of the deal, Chairman, President, and Chief Executive Officer Steve MacMillan will retire. MacMillan, 62, who has led Hologic since 2013, described his tenure as "the greatest honor and privilege" of his professional career. The company's lead independent director, Amy Wendell, expressed the board's gratitude, stating stakeholders owe him "a debt of gratitude." Hologic intends to name MacMillan's successor concurrently with the deal's closure.
The transition will trigger immediate changes for public market investors. The Nasdaq exchange will halt trading in Hologic shares (HOLX) after the market close on Monday, April 6, with a formal suspension taking effect on Tuesday, April 8. Furthermore, S&P Dow Jones Indices will remove Hologic from the S&P 500 index prior to the market open on Wednesday, April 9. Casey's General Stores (CASY) is slated to replace Hologic in the prominent benchmark index.
Deal Structure and Financials
The acquisition values Hologic at $76 per share in cash, aligning with the stock's last traded price of $76.01. However, the total headline value could reach $79 per share through a contingent value right (CVR). This additional $3 per share is payable only if Hologic's breast health division achieves specific sales targets during fiscal years 2026 and 2027. The deal received shareholder approval in February.
Blackstone and TPG are the primary acquirers, with minority investment participation from sovereign wealth funds Abu Dhabi Investment Authority (ADIA) and Singapore's GIC. The buyers have characterized Hologic as "an outstanding global leader" in women's health and view the investment as "a compelling opportunity" to foster innovation in the healthcare sector. Their strategy hinges on the belief that private ownership can accelerate Hologic's growth in a competitive market dominated by large players like Siemens Healthineers (SIEGY) and GE HealthCare (GEHC).
Company Profile and Competitive Landscape
Hologic, based in Marlborough, Massachusetts, is a leader in developing diagnostic products, medical imaging systems, and surgical equipment focused on women's health. The company is best known for its mammography systems, cervical cancer screening tests, and minimally invasive surgical devices. The acquirors have committed to maintaining the Hologic brand and its Massachusetts headquarters post-transaction.
The company operates in a competitive global medtech environment. Its annual filings identify Siemens Healthineers and GE HealthCare as primary rivals in breast and skeletal health. In the cytology and cervical cancer screening segment, Becton Dickinson (BDX) is noted as a key competitor. The move to private ownership is intended to provide Hologic with greater strategic flexibility outside of public market pressures to navigate this landscape.
Recent Performance and Final Hurdles
Hologic's business has demonstrated steady, albeit uneven, growth leading up to the acquisition. For its most recent quarter, the company reported a 2.5% increase in revenue to $1.05 billion. Segment performance was mixed: breast health sales grew 1.8%, while surgical revenue surged 8.7%. The company noted that tariffs imposed a $15.3 million cost, pressuring margins.
While all regulatory approvals are secured, the company notes the closing remains subject to the satisfaction or waiver of other customary closing conditions. Hologic has also cautioned investors about potential risks, including litigation, transaction-related expenses, and operational disruptions affecting employees, customers, or partners. The full $79 per share payout remains contingent on the future performance of the breast health business.
The acquisition represents a significant exit from the public markets for a major healthcare technology firm, underscoring continued private equity interest in stable, niche healthcare sectors with strong growth profiles.
